Home › Merck Receives Complete Response Letter for Suvorexant, Mercks Investigational Medicine for Insomnia
 

Keywords :   


Merck Receives Complete Response Letter for Suvorexant, Mercks Investigational Medicine for Insomnia

2013-07-01 14:00:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application for suvorexant, Mercks investigational medicine for the treatment of insomnia. In the Complete Response Letter, the FDA advised Merck that: Language:  English Contact:  MerckMedia Contacts:Steve Cragle, 415-845-1256orTracy Ogden, 267-305-2301orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: complete response letter medicine

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.09Weekly Recap: AkzoNobel, BASF, Axalta, PPG Top This Weeks Stories
28.09Post-Tropical Cyclone Helene Public Advisory Number 20
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Forecast Discussion Number 10
28.09Hurricane Isaac Wind Speed Probabilities Number 10
28.09Hurricane Isaac Public Advisory Number 10
28.09Summary for Hurricane Isaac (AT5/AL102024)
28.09Hurricane Isaac Forecast Advisory Number 10
More »